Data repository for kidney diseases and related conditions
Official title: Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Run by The Rogosin Institute · NCT01802034 · Data updated 2026-11-12
This study is collecting health information and samples from people with different kidney diseases to see how various factors affect their condition and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | The Rogosin Institute Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | February 2013 |
| Main results expected | August 2028 |
| Study ends | August 2028 |
| Registry record updated | April 4, 2025 |
| Trial ID | NCT01802034 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with various kidney diseases, including those requiring a kidney biopsy or those with diabetes-related kidney issues.
✕Probably not a fit
Patients who are unable to provide informed consent or do not have any form of kidney disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
RENAL AID is an observational initiative aimed at collecting extensive data and biospecimens from individuals with various kidney diseases, including diabetic nephropathy and lupus nephritis. The study will link demographic, clinical, laboratory, and genetic information into a single electronic repository to uncover relationships between these data sets. By analyzing these connections, researchers hope to identify factors that predict disease progression and response to therapy, as well as non-invasive markers that correlate with renal biopsy findings. This comprehensive approach will facilitate a better understanding of kidney diseases and improve diagnostic methods.
Why it matters
Potential benefit: If successful, this initiative could lead to improved non-invasive diagnostic methods and better management of kidney diseases.
How similar studies have gone: Other studies utilizing similar data repository approaches have shown promise in identifying disease markers and improving patient outcomes, suggesting that this methodology is both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: All Groups: * Males or females * 18 years of age and older * Willing and able to provide informed consent Native Biopsy Tissue Group: \- Require an initial kidney biopsy for medical necessity Native Kidney, Non-tissue Group: * Previously had a kidney biopsy and the tissue is not stored in this biorepository; or * Have diabetes and kidney disease and have not had a kidney biopsy Allograft Tissue Group: \- Have undergone a renal transplant and require a transplant biopsy for either surveillance or "for-cause" indications. Key Exclusion Criteria for all Groups: \- Inability to provide informed consent.
Where it's running
-
The Rogosin Institute
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Alan S Perlman, M.D. — The Rogosin Institute
- Study coordinator: Nelson Chen, M.A.
- Email: nec9039@nyp.org
- Phone: 646-317-0785
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-term zigakibart treatment for adults with IgA nephropathy
Adults with IgA nephropathy who finished an earlier zigakibart trial will receive ongoing subcutaneous zigakibart every two weeks to see if it stays safe and helps over the long term.
-
Sparsentan for IgA Nephropathy: safety and activity in adults with incident IgAN and recurrent IgAN after transplant
This trial tests whether sparsentan can be safely given and help kidney outcomes in adults with immunoglobulin A nephropathy, including people newly diagnosed who haven’t had ACEI/ARB therapy and people with recurrent IgAN after kidney transplant.
-
Umbilical Cord Mesenchymal Stem Cells for Diabetic Kidney Disease
This study tests whether injecting human umbilical cord mesenchymal stem cells can help people with diabetic nephropathy by reducing kidney inflammation and damage.
-
TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis
This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.
-
Lactoferrin Supplement in Diabetic Kidney Disease
Scientists test whether adding lactoferrin helps people with diabetic nephropathy who also have moderately to severely increased urinary albumin.
-
Golcadomide pharmacokinetics and safety in severe kidney impairment and ESRD
This study tests how golcadomide behaves in the body and whether it is safe in adults with severe kidney problems or end-stage kidney disease, compared with people with normal kidney function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.